Please assess the completion status of the following clinical trial:

Trial Title: Short Course of Amoxicillin for Erysipelas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females ≥ 18 years of age~* First episode of erysipelas of a lower leg defined as~  * acute well delineate inflammation than had lasted less than 5 days~ * T°≥ 38°5 at least once during the past 5 days or chills.~ * Score ≥3 : oedema, erythema, pain each scored from 0 to 3 : 0= none, 1= moderate, 3= severe~* Written informed consent provided by the patient~* available health insurance~* accept conditions of the trial~Exclusion Criteria:~* Erysipelas for more than 5 days~* Score \< 3~* Septic shock~* Clinical signs of necrotizing cellulitis or fasciitis, bullous lesions related to necrosis, purpuric lesions or superficial cutaneous necrosis.~* Past history of erysipelas of the same lower leg~* Erysipelas not on the lower leg~* Bilateral erysipelas~* Bite occuring during the preceding 7 days.~* Diabetic foot~* patients who have previously received systemic antibiotherapy within the last 5 days (except one or two doses within last 24 hours)~* History of any hypersensitivity or allergic reaction to beta-lactam drugs~* Known renal or Hepatic failure~* Known HIV infection~* Female patients who are pregnant, lactating (breast milk feeding), or who are of child bearing potential and not using an acceptable method of birth control~* Impossibility to stop immunosuppressive treatment, systemic corticosteroids or nonsteroidal anti-inflammatory drugs.~* Severe gastrointestinal disease, dysphagia or any pathology preventing oral administration of treatment.~* Denied to sign written informed consent~* Unable or unwilling to adhere to the study-specified procedures and restrictions~* Evolutive cancer under treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1:Short treatment (Type: EXPERIMENTAL): amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day 6 days.
- 2:Usual treatment (Type: ACTIVE_COMPARATOR): amoxicillin 50 mg/kg/24H ; I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day up to day 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).